uniQure (NASDAQ:QURE) Rating Increased to Hold at Wall Street Zen

uniQure (NASDAQ:QURE) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Sunday.

QURE has been the topic of a number of other reports. Cantor Fitzgerald raised their target price on shares of uniQure from $47.00 to $80.00 and gave the company an “overweight” rating in a research note on Thursday, September 25th. William Blair reissued a “market perform” rating on shares of uniQure in a report on Tuesday, November 11th. Mizuho lifted their price objective on shares of uniQure from $30.00 to $60.00 and gave the stock an “outperform” rating in a report on Thursday, September 25th. Wells Fargo & Company cut their target price on shares of uniQure from $80.00 to $60.00 and set an “overweight” rating for the company in a research report on Wednesday, November 12th. Finally, Leerink Partners lowered their price target on uniQure from $68.00 to $60.00 and set an “outperform” rating on the stock in a research report on Monday, November 10th. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, uniQure currently has a consensus rating of “Moderate Buy” and a consensus price target of $64.42.

uniQure Trading Down 0.5%

Shares of QURE stock opened at $27.49 on Friday. The company has a market capitalization of $1.71 billion, a PE ratio of -7.01 and a beta of 0.59. uniQure has a 52-week low of $5.89 and a 52-week high of $71.50. The business’s fifty day moving average is $45.78 and its 200 day moving average is $25.81. The company has a debt-to-equity ratio of 1.53, a quick ratio of 9.98 and a current ratio of 9.98.

uniQure (NASDAQ:QURE) last posted its earnings results on Monday, November 10th. The biotechnology company reported ($1.38) EPS for the quarter, missing the consensus estimate of ($0.85) by ($0.53). The business had revenue of $3.70 million for the quarter, compared to analysts’ expectations of $4.46 million. uniQure had a negative return on equity of 1,010.74% and a negative net margin of 1,387.98%. On average, equities research analysts anticipate that uniQure will post -3.75 EPS for the current fiscal year.

Insider Buying and Selling at uniQure

In other news, Director Jack Kaye sold 38,810 shares of the business’s stock in a transaction dated Tuesday, November 4th. The stock was sold at an average price of $30.34, for a total value of $1,177,495.40. Following the completion of the sale, the director owned 20,439 shares of the company’s stock, valued at approximately $620,119.26. The trade was a 65.50% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Matthew C. Kapusta sold 226,316 shares of the stock in a transaction dated Wednesday, September 24th. The shares were sold at an average price of $41.46, for a total value of $9,383,061.36. Following the sale, the chief executive officer owned 651,454 shares of the company’s stock, valued at $27,009,282.84. This represents a 25.78% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 314,560 shares of company stock valued at $12,362,568. Company insiders own 4.79% of the company’s stock.

Institutional Trading of uniQure

Institutional investors have recently made changes to their positions in the stock. CIBC Private Wealth Group LLC bought a new position in shares of uniQure in the third quarter worth approximately $50,000. Financial Engines Advisors L.L.C. bought a new stake in uniQure in the 3rd quarter worth $278,000. Alyeska Investment Group L.P. purchased a new position in shares of uniQure in the third quarter valued at about $2,335,000. Velan Capital Investment Management LP purchased a new position in shares of uniQure in the third quarter valued at about $1,868,000. Finally, Sassicaia Capital Advisers LLC bought a new position in shares of uniQure during the third quarter valued at about $934,000. Hedge funds and other institutional investors own 78.83% of the company’s stock.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.